loading
Precedente Chiudi:
$38.80
Aprire:
$38.8
Volume 24 ore:
65,939
Relative Volume:
0.09
Capitalizzazione di mercato:
$2.23B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
3.3759
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
+2.56%
1M Prestazione:
-3.98%
6M Prestazione:
+9.15%
1 anno Prestazione:
-16.90%
Intervallo 1D:
Value
$38.15
$39.19
Intervallo di 1 settimana:
Value
$35.92
$39.69
Portata 52W:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Nome
Agios Pharmaceuticals Inc
Name
Telefono
617-649-8600
Name
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Dipendente
488
Name
Cinguettio
@AgiosPharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
AGIO's Discussions on Twitter

Confronta AGIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
38.34 2.18B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.60 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.19 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
451.61 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
693.76 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
315.76 37.96B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Iniziato H.C. Wainwright Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-10 Ripresa Raymond James Outperform
2024-09-27 Downgrade Leerink Partners Outperform → Market Perform
2024-02-08 Iniziato Cantor Fitzgerald Overweight
2023-02-03 Iniziato Piper Sandler Overweight
2022-11-17 Aggiornamento Goldman Sell → Neutral
2022-07-27 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-12-03 Iniziato BofA Securities Buy
2021-07-30 Downgrade Goldman Neutral → Sell
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-10 Iniziato H.C. Wainwright Buy
2021-03-01 Downgrade JP Morgan Overweight → Neutral
2021-03-01 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-02-26 Downgrade SVB Leerink Outperform → Mkt Perform
2020-10-22 Aggiornamento Barclays Equal Weight → Overweight
2020-03-04 Iniziato Barclays Equal Weight
2019-11-26 Iniziato Cantor Fitzgerald Overweight
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
2019-05-23 Ripresa Goldman Neutral
2019-02-15 Aggiornamento SVB Leerink Mkt Perform → Outperform
2018-09-25 Iniziato Leerink Partners Mkt Perform
2018-05-23 Iniziato Citigroup Buy
2018-04-11 Reiterato Credit Suisse Outperform
2018-02-15 Reiterato Needham Buy
2018-02-15 Reiterato SunTrust Buy
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-08-10 Reiterato Needham Buy
2017-08-08 Reiterato SunTrust Buy
2017-08-02 Aggiornamento Leerink Partners Mkt Perform → Outperform
2017-06-26 Downgrade Janney Buy → Neutral
2017-01-17 Aggiornamento Oppenheimer Perform → Outperform
2016-10-24 Iniziato Needham Buy
2016-06-13 Aggiornamento JP Morgan Neutral → Overweight
2016-05-18 Reiterato SunTrust Buy
Mostra tutto

Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie

pulisher
Aug 16, 2025

Can Agios Pharmaceuticals Inc. withstand a market correction2025 Sector Review & Consistent Growth Equity Picks - sundaytimes.kr

Aug 16, 2025
pulisher
Aug 15, 2025

How to track smart money flows in Agios Pharmaceuticals Inc.Earnings Overview Report & Advanced Swing Trade Entry Plans - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Performance Recap & Long-Term Safe Return Strategies - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

What makes Agios Pharmaceuticals Inc. stock price move sharplyJuly 2025 Movers & AI Optimized Trade Strategies - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Can Agios Pharmaceuticals Inc. generate free cash flowCEO Change & Weekly Sector Rotation Insights - thegnnews.com

Aug 14, 2025
pulisher
Aug 13, 2025

Published on: 2025-08-13 06:00:50 - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

How institutional ownership impacts Agios Pharmaceuticals Inc. stockJuly 2025 Action & Weekly High Potential Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Can Agios Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Entry and Exit Point Tips From Traders - 선데이타임즈

Aug 12, 2025
pulisher
Aug 12, 2025

Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire

Aug 12, 2025
pulisher
Aug 11, 2025

Full technical analysis of Agios Pharmaceuticals Inc. stockLow Exposure Strategy with Sector Analysis - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

How Agios Pharmaceuticals Inc. stock performs during market volatilityMachine Learning Stock Price Forecast Tool - Newser

Aug 11, 2025
pulisher
Aug 09, 2025

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance

Aug 08, 2025
pulisher
Aug 07, 2025

Agios Pharmaceuticals Shares Plunge 23% Amid Safety Concerns - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

TR | OpenAI4o Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $38 - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

Can a trend reversal in Agios Pharmaceuticals Inc. lead to recoveryChart Driven Entry Timing for Swing Trades - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Agios Shares Fall 15% After Report of Deaths Among Pyrukynd Patients - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com

Aug 05, 2025
pulisher
Aug 05, 2025

Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech

Aug 05, 2025
pulisher
Aug 05, 2025

Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace

Aug 05, 2025
pulisher
Aug 05, 2025

Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

Envestnet Asset Management Inc. Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns - Asianet Newsable

Aug 05, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria

Aug 04, 2025
pulisher
Aug 04, 2025

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times

Aug 04, 2025
pulisher
Aug 04, 2025

Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan

Aug 04, 2025
pulisher
Aug 04, 2025

Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru

Aug 04, 2025
pulisher
Aug 04, 2025

Agios evaluating fourth Pyrukynd case after analyst report - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals Becomes Oversold (AGIO) - Nasdaq

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 03, 2025

How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Aug 02, 2025
pulisher
Aug 01, 2025

Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN

Aug 01, 2025

Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Agios Pharmaceuticals Inc Azioni (AGIO) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Smith Cynthia
Director
Aug 11 '25
Option Exercise
0.00
2,302
0
12,414
Goff Brian
Chief Executive Officer
Aug 08 '25
Option Exercise
0.00
22,691
0
134,613
Goff Brian
Chief Executive Officer
Aug 08 '25
Sale
36.67
11,085
406,487
123,528
$24.68
price down icon 0.12%
$85.11
price up icon 0.57%
$26.38
price up icon 0.00%
$109.86
price down icon 0.90%
$131.43
price down icon 0.31%
biotechnology ONC
$315.76
price up icon 0.64%
Capitalizzazione:     |  Volume (24 ore):